Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5723MR)

This product GTTS-WQ5723MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5723MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8317MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ7556MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ1386MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ6377MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ10927MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ2907MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ12163MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ13430MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW